Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 71

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Pancreatic carcinoma

Not recruiting

Study on Sonoporation-Enhanced Treatment with Gemcitabine, Nab-Paclitaxel, and FOLFIRINOX for Patients with Inoperable Pancreatic Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Helse Bergen HF

Colorectal cancer metastatic

Not recruiting

Study on Personalized Treatment for Metastatic Colorectal Cancer Using Regorafenib for Patients with Advanced Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Regorafenib
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Colorectal cancer metastatic

Not recruiting

Study on Tocotrienol and Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Lillebaelt Hospital

Oesophageal carcinoma

Not recruiting

Study on the Safety of Radiation and Nivolumab for Patients with Esophageal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Oslo University Hospital HF

Colon cancer

Not recruiting

Study on the Effects of Capecitabine and Oxaliplatin in Patients with Locally Advanced Colon Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Lillebaelt Hospital

Colorectal cancer metastatic+1

Not recruiting

Study Comparing Avelumab and Standard Chemotherapy for Patients with Metastatic Colorectal Cancer with Microsatellite Instability

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Fondation Franc.Cancerologie Digestive

Oesophageal carcinoma

Not recruiting

Study of Nivolumab for Patients with Esophageal Cancer Undergoing Active Surveillance After Chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Rectal cancer

Not recruiting

Study on Capecitabine and Oxaliplatin for Patients with High Risk Rectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Colorectal cancer stage II+1

Not recruiting

Study of Drug Combination Treatment (Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan) Guided by Liquid Biopsy Testing in Patients with Stage III and High-Risk Stage II Colon Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Colorectal cancer metastatic

Not recruiting

Study on the Safety and Effectiveness of Etrumadenant, Quemliclustat, and Zimberelimab in Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcus Biosciences Inc.

Colorectal cancer

Not recruiting

Study of Nivolumab, Ipilimumab, Relatlimab, and Daratumumab in Patients with Recurrent and Metastatic Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Bristol Myers Squibb International Corporation

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SGM-101 fluorescent imaging agent to guide surgery in patients with pancreatic cancer who received prior treatment

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.